The question gets asked constantly and answered badly. Half the results say “yes, completely legal,” half say “no, the FDA banned them,” and neither side explains the actual legal structure well enough for a reader to reason about their own situation.
The honest answer has three parts. Most research peptides are not controlled substances under federal law. Almost none of them are approved drugs. And the thing regulators act on is not the molecule itself but what a seller says the molecule is for.
This post covers United States law and is written for people buying, selling, or handling these compounds in a research context. It is general information, not legal advice. The not-legal-advice line at the end is not boilerplate padding; consult an attorney before making decisions about your own operation.
The short answer
As of this writing:
- Research peptides as a class are not scheduled controlled substances in the United States. Possessing or shipping them is not a Controlled Substances Act offense the way possessing anabolic steroids can be.
- Most of them are not FDA-approved drugs either. A handful are approved as prescription pharmaceuticals under specific brand names. The rest have no approval for any use.
- The legal exposure sits in how they are marketed and labeled, not in the chemistry. Selling a compound for laboratory research is treated differently from selling the same compound with claims about what it does in a person.
That last point is the one everything else hangs on, so it is worth going slowly.
Controlled substances: what “scheduled” means
The Controlled Substances Act sets up five schedules of drugs with escalating restrictions. Being on a schedule triggers registration requirements, recordkeeping obligations, and criminal penalties for unregistered distribution.
Anabolic steroids sit on Schedule III. Congress put them there through the Anabolic Steroid Control Act of 1990, expanded the definition in 2004, and expanded it again through the Designer Anabolic Steroid Control Act of 2014. That last one matters because it gave the DEA a faster path to add new steroid analogs. The result is a category where the class itself is scheduled, not just individual named molecules.
Research peptides have no equivalent. There is no Peptide Control Act. Compounds like BPC-157, the growth hormone secretagogues, the thymosin fragments, and the cognitive-research compounds are not listed on any federal schedule, individually or as a class. That is a genuine and meaningful difference from steroids, and it is the single most common point of confusion in this category. We cover the chemistry and mechanism side of it in are peptides steroids.
One federal carve-out is worth knowing because it is frequently missed. Human growth hormone is restricted separately under 21 U.S.C. 333(e), which makes it a federal felony to distribute, or possess with intent to distribute, hGH for any use other than treatment of a disease or recognized medical condition where that use has been authorized by FDA and the treatment is under a physician’s order. A valid prescription for an unapproved use does not satisfy the statute - that is precisely what makes it stricter than ordinary off-label rules. That statute is not the Controlled Substances Act and hGH is not scheduled, but the practical restriction is severe. It applies to somatropin itself, not to the growth hormone secretagogue peptides that are often discussed alongside it, which are a different class of molecule with a different regulatory posture.
The distinction regulators actually act on
Under the Federal Food, Drug, and Cosmetic Act, whether something is a “drug” turns substantially on intended use. FDA determines intended use from labeling, advertising, promotional material, and the circumstances surrounding the sale. The relevant regulation is 21 CFR 201.128.
This is why two sellers can ship the identical molecule from the identical batch and be in completely different positions.
Seller A lists the compound with its molecular weight, purity spec, storage conditions, and a research-use-only statement. No dosing. No claims about outcomes in people. No comparison to a prescription product.
Seller B lists the same compound under a headline about fat loss, includes an administration schedule, references a trademarked pharmaceutical brand name for comparison, and posts customer photos.
Seller B has, in regulatory terms, marketed an unapproved new drug and misbranded it. The molecule was never the problem. The page was.
“Research use only” is not a magic phrase. It is a description of what the product is being sold for, and it only holds if the rest of the operation matches. A site that carries the disclaimer in the footer and dosing charts in the product descriptions has not created a safe harbor; it has created a contradiction that any reviewer will resolve against it. Intended use is read from the whole picture, including what the seller knows about how buyers are using the product.
Unapproved new drug and misbranding: the two charges that show up
Nearly every FDA warning letter in this category cites some combination of the same two theories.
Unapproved new drug. A product intended to diagnose, treat, cure, or prevent disease, or to affect the structure or function of the body, is a drug. A drug that has not gone through the approval process cannot be introduced into interstate commerce. Marketing claims are what convert a chemical into a drug for this purpose.
Misbranded drug. A drug whose labeling lacks adequate directions for use, or is false or misleading, is misbranded. Because an unapproved drug cannot have adequate directions for a legal use, this charge tends to travel with the first one automatically.
Neither theory requires the government to show the product harmed anyone. Both are about the marketing.
The 503A bulk drug substances lists
This is the part that generates the most confused reporting, so here is the structure.
Sections 503A and 503B of the FD&C Act govern compounding pharmacies and outsourcing facilities. A compounder can work with a bulk drug substance if it meets certain conditions, one of which is appearing on an FDA list of substances that may be used in compounding. Substances get nominated for that list, and FDA sorts nominations into categories:
| Category | What it means |
|---|---|
| Category 1 | Under FDA evaluation; may be used in compounding while the review is pending, subject to conditions |
| Category 2 | FDA has identified significant safety risks; not eligible for use in compounding while in this category |
| Category 3 | Nominated without sufficient supporting information for FDA to evaluate |
In 2023, FDA placed a set of peptides into Category 2, meaning the agency had identified significant safety risks for compounding purposes. BPC-157 was the best known example and is the one most often cited in coverage of this issue. Then the position reversed: in April 2026, following a directive from HHS, FDA removed twelve peptides from Category 2 - including BPC-157, the thymosin beta-4 fragment sold as TB-500, Semax, KPV, and GHK-Cu - and sent seven of them to its Pharmacy Compounding Advisory Committee in July 2026 for review toward possible addition to the approved bulk-substances list. Removal from Category 2 is not approval: these substances were not moved to Category 1, and compounding them still sits outside FDA’s interim enforcement-discretion policy while the review runs. The lists move, in both directions, so anyone with a specific compound in question should check FDA’s current published list rather than rely on a blog post.
Two things this does and does not mean:
- It did mean, while the Category 2 placement stood, that a compounding pharmacy could not lawfully compound preparations using that substance. That closed a real distribution channel between 2023 and early 2026 and is a large part of why the market shifted in those years.
- It does not mean the substance became a controlled substance, or that possessing it became a criminal act, or that it was “banned” in the broad sense the word usually implies. The list governs compounding eligibility. It is a restriction on one specific regulated activity.
Reporting that collapses those two into “the FDA banned peptides” is wrong in a way that matters, because it leads people to make decisions based on a rule that does not exist while ignoring the rules that do.
Separately, when FDA declared the semaglutide and tirzepatide shortages resolved in late 2024 and early 2025, the shortage-based allowances that had let compounders produce those specific molecules ended. That is a different mechanism from the bulks lists, and it drove a distinct wave of enforcement activity aimed at sellers who kept going. For the current approval picture across this category, see what peptides are FDA approved.
What the 2023-2026 enforcement wave actually targeted
Reading through the warning letters and joint FDA/FTC actions from this period, the pattern is consistent. The letters go to sellers who did specific things.
| Draws enforcement | Generally does not |
|---|---|
| Disease and treatment claims (“treats,” “cures,” “reverses”) | Descriptions of published research findings, attributed |
| Body-composition and performance claims aimed at consumers | Molecular weight, sequence, purity spec, storage conditions |
| Dosing schedules and administration instructions | Stating a compound is not for human consumption and meaning it |
| Using trademarked pharmaceutical brand names to sell an unapproved product | Using the compound’s generic or research name |
| Testimonials and before/after content from human users | No consumer testimonials |
| Marketing a compounded copy of a molecule after its shortage allowance ended | Research supply of unapproved research compounds, labeled as such |
The research supply model itself was not the target. Sellers who moved marketing into consumer-outcome territory were. This is a distinction that vendors in this category have a commercial incentive to blur, and readers should be skeptical of anyone who tells them the line is anywhere other than where the letters put it.
If you are building a business in this space, the compliance section of how to start a peptide company covers the operational side of staying on the right side of that line.
State law varies
Federal law is not the whole picture. States maintain their own controlled substance schedules and can schedule substances the federal government has not. States also run their own consumer protection statutes, and state attorneys general have brought actions in this category independently of federal regulators. Wholesale drug distribution licensing is a state-level regime in most of the country, and whether it applies to a given operation depends on how the products are classified and marketed.
Practically: a business model that is fine in one state may carry a licensing requirement in another. This is an attorney question, not a research question, and it is worth answering before rather than after opening an account.
Import and customs
Buying across borders adds a separate layer that has nothing to do with whether a compound is legal to possess where you live.
FDA has authority over imported products and can detain or refuse shipments it determines to be unapproved new drugs. Customs authorities can hold packages independently. Neither action requires a criminal charge, and in many cases the practical outcome is simply that the shipment does not arrive.
Country rules vary enormously. Some jurisdictions treat these compounds as prescription-only medicines regardless of stated purpose. Some regulate them as research chemicals with no import restriction at the individual level. Some have no clear category and enforce inconsistently. Our country-specific guides walk through the rules jurisdiction by jurisdiction, starting with how to buy peptides in the United Kingdom.
For US buyers specifically, there is one consideration that does not come up often enough: a customs interaction can affect trusted traveler status. If you hold Global Entry, TSA PreCheck, NEXUS, or SENTRI, an international shipment held at the border is a different kind of risk than it is for someone who does not. We wrote that up in detail on our Global Entry and customs page, including how the two shipping lines we run differ on this point.
WADA prohibition is a separate question
Athletes subject to anti-doping rules face a rule set that has nothing to do with criminal or regulatory law.
The World Anti-Doping Agency publishes a Prohibited List. Peptide hormones, growth factors, and related substances sit in class S2, and non-approved substances with no current regulatory approval anywhere sit in class S0, which is a catch-all covering compounds still in preclinical or clinical development. BPC-157 was added to the Prohibited List effective January 1, 2022 under S0. Growth hormone secretagogues and thymosin beta-4 are covered under S2.
A substance can be entirely lawful to possess and still cost a tested athlete their eligibility. These are two independent systems, and confusing them in either direction is a mistake. If you are subject to testing, the Prohibited List is the document that governs you, not the Controlled Substances Act.
How this shapes what a research supplier can and cannot do
Since this comes up: a supplier operating the research model has a fixed set of things it will not do, and the reason is the intended-use doctrine above rather than squeamishness.
We do not provide dosing information, administration guidance, or handling protocols. We do not make claims about outcomes in people. We do not use pharmaceutical brand names to describe our compounds. Everything we sell is stated as being for laboratory and research use only and not for human consumption, and that statement is meant literally.
If a vendor in this category will give you a dosing chart, they have told you something about how they think about regulatory risk, and by extension about how long they intend to be around. For background on what this category actually is, see what are research peptides.
Frequently asked questions
Are peptides controlled substances in the US?
As of this writing, research peptides as a class are not listed on any federal drug schedule. This is a real distinction from anabolic steroids, which are Schedule III. Human growth hormone is restricted under a separate statute, 21 U.S.C. 333(e), even though it is not scheduled. Individual state schedules can differ from the federal list, so a specific compound in a specific state is worth checking.
Is it legal to buy peptides for research?
Purchasing unapproved research compounds for laboratory research use is not prohibited by federal statute in the way a scheduled substance would be. The regulatory questions attach mainly to sellers, through the unapproved new drug and misbranding theories, and turn on how the products are marketed and labeled. Buyers in institutional settings usually have their own internal compliance requirements that are stricter than the law.
Did the FDA ban BPC-157?
Not in the sense most people mean, and the situation has moved. FDA placed BPC-157 in Category 2 of its 503A bulk drug substances evaluation in 2023, which blocked compounding pharmacies from using it while the placement stood - a restriction on compounding, not a scheduling action and not a possession ban. In April 2026, FDA removed BPC-157 and eleven other peptides from Category 2 following an HHS directive, and referred several of them for advisory committee review. Removal is not approval - compounding is not green-lit while the review runs - but “the FDA banned BPC-157” was an overstatement even before the reversal, and it is simply out of date now.
Why do some vendors get FDA warning letters and others do not?
Because the letters follow marketing conduct. The recurring triggers are disease or body-composition claims, dosing and administration instructions aimed at consumers, use of trademarked pharmaceutical brand names, human testimonials, and continuing to sell compounded copies of molecules after a shortage allowance ended. Vendors who describe compounds in research terms without those elements are in a materially different position.
Does legal status differ by country?
Substantially. Some countries treat these compounds as prescription-only medicines regardless of the stated purpose, some regulate them as research chemicals, and some have no clear classification. Import rules are a separate layer from possession rules in most jurisdictions. Our country guides cover this jurisdiction by jurisdiction.
The bottom line
Most research peptides are not scheduled. Most are not approved. The exposure lives in claims and labeling, not in the molecule, and the enforcement record from 2023 through 2026 supports that reading consistently. State law adds variation, import adds a separate risk layer, and anti-doping rules run on a track of their own.
This is general information about how the regulatory structure is built. It is not legal advice, it does not account for your jurisdiction or your specific facts, and regulations in this category have changed repeatedly in recent years. Consult a qualified attorney before making decisions about buying, selling, importing, or handling these compounds.